Aim In order to increase the database related to the antineoplastic potential of metformin, association between the use of metformin and risk of cancer occurence in patients with diabetes mellitus type 2 (DM2) was investigated. Methods In this cross-sectional study, medical records of patients with DM2 were reviewed for cancer occurence. Data on age, body mass index (BMI), alcohol and nicotine consumption, glucose and HbA1c levels, duration of DM2, medication used in the treatment of DM2 and cancer occurence were collected and analyzed. Unpaired Student's t-test or Mann-Whitney U test were used for comparisons between treatment groups, and logistic regression to asses how well our set of predictor variables predicts occurence of carcinoma. P-value less than 0.05 was considered statistically significant. Results The mean age of 234 included patients was 66.8±11.5 years, and DM2 duration was 7± 6.49 years. Mean glucose value was 8.51±4.17mmol/L, and HbA1c 7.74±1.53. Metformin therapy was prescribed in 190 (81%) patients. Cancer was diagnosed in 16 (6.8%) patients: prostate cancer in eight (3.4%), breast cancer in four (1.7%), rectal cancer in two (0.9%) and cancer of the uterus and cervix in one patient. Age, duration of DM2 and BMI did not contribute significantly to the model, while metformin use was shown to be a significant independent predictor (OR=0.049; 95% CI=0.013-0.181; p=0.001). Conclusion Our findings support the hypothesis that the use of metformin compared to the use of other oral antidiabetic drugs is associated with a lower risk of cancer in patients with DM2.
Gandini S, Puntoni M, Heckman-Stoddard B, Dunn B, Ford L, Censi D, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 2014. p. 867–85.
2.
Libby G, Donnelly L, Donnan P. New users of metformin area at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009. p. 1620–5.
3.
Godarzi M, Ash B, M. Metformin revisited: reevaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab. 2005. p. 654–65.
4.
Gosmanova E, Canada R, Mangold T, Rawls W, Wall B. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. Am J Med Sci. 2008. p. 241–7.
5.
Evans J, Ogston S, Emslie-Smith A, Morris A. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006. p. 930–6.
6.
Evans J, Donnelly L, Smith E, Alessi A, Morris D, A. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005. p. 1304–5.
7.
Bowker S, Majumdar S, Veugelers P, Johnson J. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006. p. 254–8.
8.
Lemke T, Williams D, Roche V, Zito S. Foye’s principles of medicinal chemistry. 6 th ed. Philadelphia. Lippincott Williams & Willkins; 2008.
9.
Viollet B, Guigas B, Garcia S, Leclerc N, Foretz J, Andreelli M, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2012. p. 253–70.
10.
Mičić D, Cvijović G, Trajković V, Duntas L, Metformin P. its emerging role in oncology. Hormones. 2011. p. 5–15.
11.
Sun G, Kashyap S. Cancer risk in type 2 diabetes mellitus: metabolic Llnks and therapeutic considerations. J Nutr Metab. 2011. p. 708183.
12.
Li W, Saud S, Young M, Chen G, Hua B. Targeting AMPK for cancer prevention and treatment. Oncotarget. 2015. p. 7365–78.
13.
Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 2010. p. 457–70.
14.
Thompson M, Grubbs C, Bode A, Reid J, Mcgovern R, Bernard P, et al. Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. Cancer Prev Res. 2015. p. 231–9.
15.
Anisimov V, Berstein L, Popovich I, Zabezhinski M, Egormin P, Piskunova T, et al. Poroshina TE. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY). 2011. p. 148–57.
16.
Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012. p. 33411.
17.
Franciosi M, Lucisano G, Lapice E, Strippoli G, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013. p. 71583.
18.
Li KL, Li L, Zhang P, Kang J, Wang YB, Chen HY, et al. A multicenter double-blind phase II study of metformin with gefitinib as first-line therapy of locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2017. p. 340–3.
19.
Cancer Research UK. Cancer incidence by age.
20.
Calle E, Rodriguez C, Walker-Thurmond K, Thun M. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003. p. 1625–38.
21.
Togashi Y, Hayashi H, Okamoto K, Fumita S, Terashima M, De Velasco M, et al. Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. Lung Cancer. 2015. p. 16–23.
22.
Cancer facts and figures. American Cancer Society; 2017.
23.
Larsson S, Mantzoros C, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007. p. 856–62.
24.
Friberg E, Orsini N, Mantzoros C, Wolk A. Diabetes mellitus and risk of endometrial cancer: a metaanalysis. Diabetologia. 2007. p. 1365–74.
25.
Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012. p. 109–22.
26.
El-Serag H, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006. p. 369–80.
27.
Huxley R, Ansary-Moghaddam A, De González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005. p. 2076–83.
28.
Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer. 2013. p. 310.
29.
Mitri J, Castillo J, Pittas A. Diabetes and risk of non-Hodgkin’s lymphoma: A meta-analysis of observational studies. Diabetes Care. 2008. p. 2391–7.
30.
Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012. p. 1576–85.
31.
Barone B, Yeh H, Snyder C, Peairs K, Stein K, Derr R, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008. p. 2754–64.
32.
Garg S, Maurer H, Reed K, Selagamsetty R. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab. 2014. p. 97–110.
33.
Onitilo A, Stankowski R, Berg R, Engel J, Glurich I, Williams G, et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev. 2014. p. 134–40.
34.
Margel D, Urbach D, Lipscombe L, Bell C, Kulkarni G, Austin P, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst. 2013. p. 1123–31.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
